Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- BAVA.CO
- Price
- 200.00
- Stock movement down
- -1.20 (-0.62%)
- Company name
- Bavarian Nordic
- Exchange
- (CO ,
- Currency
- DKK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 15.02B
- Ent value
- 14.93B
- Price/Sales
- 2.18
- Price/Book
- 1.14
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 6.14
- Forward P/E
- 19.66
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 10.63%
- 3 year return (CAGR)
- -5.37%
- 5 year return (CAGR)
- -3.88%
- 10 year return (CAGR)
- 0.57%
Last updated: 2026-02-13
DIVIDENDS
BAVA.CO does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 6.14 |
| Price to OCF | 4.80 |
| Price to FCF | 11.70 |
| Price to EBITDA | 8.19 |
| EV to EBITDA | 8.14 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2.18 |
| Price to Book | 1.14 |
| EV to Sales | 2.17 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 78.24M |
| EPS (TTM) | 31.24 |
| FCF per share (TTM) | 16.40 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 6.89B |
| Gross profit (TTM) | 3.74B |
| Operating income (TTM) | 2.49B |
| Net income (TTM) | 2.44B |
| EPS (TTM) | 31.24 |
| EPS (1y forward) | 9.77 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 54.33% |
| Operating margin (TTM) | 36.21% |
| Profit margin (TTM) | 35.50% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 2.09B |
| Net receivables | 1.23B |
| Total current assets | 6.89B |
| Goodwill | 0.00 |
| Intangible assets | 6.02B |
| Property, plant and equipment | 2.19B |
| Total assets | 15.16B |
| Accounts payable | 1.10B |
| Short/Current long term debt | 134.04M |
| Total current liabilities | 1.80B |
| Total liabilities | 2.00B |
| Shareholder's equity | 13.16B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 3.13B |
| Capital expenditures (TTM) | 1.85B |
| Free cash flow (TTM) | 1.28B |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 18.58% |
| Return on Assets | 16.13% |
| Return on Invested Capital | 18.56% |
| Cash Return on Invested Capital | 9.75% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 193.15 |
| Daily high | 193.20 |
| Daily low | 189.65 |
| Daily Volume | 255K |
| All-time high | 401.70 |
| 1y analyst estimate | - |
| Beta | 1.10 |
| EPS (TTM) | 31.24 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 12 Mar 2026 |
Downside potential
Loading...
Downside potential data
| BAVA.CO | S&P500 | |
| Current price drop from All-time high | -50.21% | -0.89% |
| Highest price drop | -91.83% | -56.47% |
| Date of highest drop | 30 Sep 2002 | 9 Mar 2009 |
| Avg drop from high | -48.18% | -10.86% |
| Avg time to new high | 98 days | 12 days |
| Max time to new high | 1935 days | 1805 days |
COMPANY DETAILS
Marketcap
15.02B
Marketcap category
Large-cap
Description
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, Finland, Netherlands, Switzerland, Sweden, Taiwan, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Employees
1738
Investor relations
-
SEC filings
CEO
Country
Denmark
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Exceeding latest 2025 guidance following a strong performance from both commercial arms of the business in Travel Health and Public Preparedness.2026 guidance reflects continued growth in Travel Healt...
February 12, 2026
COPENHAGEN, Denmark, February 9, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on January 7, 2026, has now been completed, reachin...
February 9, 2026
COPENHAGEN, Denmark, February 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase sha...
February 2, 2026
Agreement to enable the first entry in Latin America for Bavarian Nordic’s chikungunya vaccinePotential to expand agreement to cover rest of Latin America COPENHAGEN, Denmark, January 23, 2026 – Bavar...
January 23, 2026
Bavarian Nordic (CPSE:BAVA) has been drawing attention after recent share moves, with the stock showing mixed returns over the past year that contrast with modest annual revenue and net income changes...
January 10, 2026
If you are wondering whether Bavarian Nordic is attractively priced right now, you are not alone. The stock has drawn attention from investors trying to work out if the current level reflects its fund...
January 10, 2026
COPENHAGEN, Denmark, January 7, 2026 – Bavarian Nordic A/S (OMX: BAVA) today launches the first tranche of the share buy-back program announced on December 2, 2025, under which the Company intends to ...
January 7, 2026
COPENHAGEN, Denmark, December 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Board of Directors has decided to establish a long-term incentive program for Executive Management as ...
December 18, 2025
COPENHAGEN, Denmark, December 17, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that, following the recent appointment of Anne Louise Eberhard as new Chair of the Board of Directors, and in a...
December 17, 2025
COPENHAGEN, Denmark, December 2, 2025 – Bavarian Nordic A/S (OMX: BAVA) today announced its intent to launch a one-time share buy-back program of up to DKK 500 million to be executed over the next 12 ...
December 2, 2025
Next page